Across TCGA pan-cancer cohorts, RNU6ATAC3P RNA differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of RNU6ATAC3P’s most consistent transcriptional readouts.

The strongest signal is observed in cholangiocarcinoma (CHOL), where RNU6ATAC3P RNA is more highly expressed in tumor relative to normal tissue. In most cancer types RNU6ATAC3P is over-expressed in tumor, although a few such as KIRC show the opposite, repressed pattern.

CHOL, LUSC, and BLCA are the cancer types where RNU6ATAC3P tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RNU6ATAC3P RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CHOL	All	II,III,IV	+1.100	<.001	3	view →
LUSC	Female	All	+0.255	.015	2	view →
BLCA	All	All	+0.191	.021	2	view →
BRCA	Female	All	+0.113	.047	2	view →
KIRC	All	IV	−0.085	.036	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: RNU6ATAC3P RNA expression & survival · all RNU6ATAC3P data types